Home Administrative Billing & Reimbursement BlueCard® Health and Wellness Medical PEAR portal Pharmacy Products Quality Management

​​Luspatercept–aamt (Reblozyl®) policy has been updated to include coverage for beta thalassemia and myelodysplastic syndromes

May 23, 2023

​Effective August 21, 2023, Independence Blue Cross and Independence Administrators will update their Luspatercept–aamt (Reblozyl®) policies to include coverage for beta thalassemia and myelodysplastic syndromes for Commercial and Medicare Advantage members.

This policy was updated to communicate the company's coverage position for beta thalassemia and myelodysplastic syndromes, in alignment with U.S. Food and Drug Administration (FDA) prescribing information and the National Comprehensive Cancer Network (NCCN). 

A baseline hemoglobin (Hgb) level of less than or equal to 11 g/dL was added as a criterion for beta thalassemia and myelodysplastic syndromes. Serum erythropoietin levels were added as criteria for lower risk (defined as International Prognostic Scoring System [IPSS-R] Very Low, Low, Intermediate) myelodysplastic syndromes.

For more information, please view the following notifications that were published on May 22, 2023:


This content was prepared for the Provider News Center and may not be reproduced in any way without the express written permission of Independence Blue Cross. Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association.
Connect with us     Facebook     Twitter     Flickr     YouTube     Walk the Talk    Independence Pinterest    Independence LinkedIn    Independence Instagram Site Map        Anti-Fraud        Privacy Policy        Legal        Disclaimer
© 2023 Independence Blue Cross.
Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association, serving the health insurance needs of Philadelphia and southeastern Pennsylvania.